Dazodalibep clinical trials
Also written VIB4920 and MEDI4920.
How each study uses dazodalibep is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the dazodalibep studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2019 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2019 | 4 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 2
Amgen (8) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · MedImmune LLC (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses dazodalibep is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- VIBRANT: VIB4920 for Active Lupus NephritisRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05201469Written as VIB4920
- A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)RecruitingPhase 3AmgenNCT06747949Written as Dazodalibep
- A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease ActivityCompletedPhase 3AmgenNCT06104124Written as Dazodalibep
- CD40L Antagonism in Rheumatoid Arthritis (RA)TerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05306353Written as VIB4920 with TNFi
- A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom StateActive, not recruitingPhase 3AmgenNCT06245408Written as Dazodalibep
- A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's SyndromeCompletedPhase 2AmgenNCT04129164Written as VIB4920
- A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney TransplantCompletedPhase 2AmgenNCT04046549Written as VIB4920
- A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid ArthritisCompletedPhase 1AmgenNCT02780388Written as VIB4920
- A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid ArthritisCompletedPhase 2AmgenNCT04163991Written as VIB4920
- Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased DonorWithdrawnPhase 2AmgenNCT04174677Written as VIB4920
- Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy AdultsCompletedPhase 1MedImmune LLCNCT02151110Written as MEDI4920 3 mg
Codes
What other systems call dazodalibep · ClinicalTrials.gg INT016787
- UNII (FDA) HN5US76BWFDAZODALIBEPOne source FDA
- NCI Thesaurus C175714DazodalibepOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | HN5US76BWF | DAZODALIBEP | One source FDA |
| NCI Thesaurus | C175714 | Dazodalibep | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.